Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Scilex Holding Company (SCLX : NSDQ)

• Company Description    Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif. Number of Employees: 115

• Price / Volume Information    Yesterday's Closing Price: $12.20 Daily Weekly Monthly 20 Day Moving Average: 70,147 shares Shares Outstanding: 8.49 (millions) Market Capitalization: $103.59 (millions) Beta: 1.36 52 Week High: $34.27 52 Week Low: $3.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -37.11% -37.01% 12 Week -31.00% -32.11% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 960 SAN ANTONIO ROAD - PALO ALTO,CA 94303 USA ph: 650-516-4310 fax: - investorrelations@scilexholding.com http://www.scilexholding.com

• General Corporate Information    Officers Jaisim Shah - Chief Executive Officer; President and Director Henry Ji - Executive Chairperson and Director Stephen Ma - Chief Financial Officer Dorman Followwill - Director Jay Chun - Director Peer Information Scilex Holding Company (CORR.) Scilex Holding Company (RSPI) Scilex Holding Company (CGXP) Scilex Holding Company (BGEN) Scilex Holding Company (GTBP) Scilex Holding Company (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 80880W205 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/13/26 Share - Related Items Shares Outstanding: 8.49 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.36 Market Capitalization: $103.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.57 EPS Growth vs. Year Ago Period: -252.26% vs. Previous Quarter: -198.79% Sales Growth vs. Year Ago Period: -26.85% vs. Previous Quarter: 6.71% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -249.89 06/30/25 - -109.95 Current Ratio 12/31/25 - - 09/30/25 - 0.05 06/30/25 - 0.11 Quick Ratio 12/31/25 - - 09/30/25 - 0.04 06/30/25 - 0.10 Operating Margin 12/31/25 - - 09/30/25 - -822.80 06/30/25 - -221.28 Net Margin 12/31/25 - - 09/30/25 - -822.80 06/30/25 - -179.12 Pre-Tax Margin 12/31/25 - - 09/30/25 - -828.52 06/30/25 - -183.01 Book Value 12/31/25 - - 09/30/25 - -23.69 06/30/25 - -35.82 Inventory Turnover 12/31/25 - - 09/30/25 - 5.60 06/30/25 - 5.06 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©